Evotec's stock rose despite downgrades from Morgan Stanley and Deutsche Bank, while HC Wainwright maintained a "buy" rating.
Evotec's stock rose to $3.30 following a $3.47 opening, amid recent downgrades from Morgan Stanley and Deutsche Bank, while HC Wainwright maintained a "buy" rating. The company, involved in drug development for various diseases, has a debt-to-equity ratio of 0.42. In contrast, EVgo reported a Q2 EPS of -$0.10, surpassing estimates, and saw a 31.8% revenue increase. Analysts rated EVgo as a "Moderate Buy" with a target price of $4.63.
September 07, 2024
3 Articles